Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Jessica D Sun

2PUBLICATIONS
53CO-AUTHORS
Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (2)

Sort by Publication Date:
|Nov 06, 2025
Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations.

Melissa R Junttila, Claire E Repellin, Sumeet Salaniwal

|Aug 23, 2024
ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors.

Christopher T Chen, Vishesh Khanna, Shivaani Kummar

Pageof 1

Frequent Collaborators

2 joint publications

Anneleen Daemen

2 joint publications

Edna Chow Maneval

2 joint publications

Pratik S Multani

2 joint publications

Melissa R Junttila

2 joint publications

Alexander I Spira

1 joint publications

Vishesh Khanna

1 joint publications

Shivaani Kummar

1 joint publications

David Sommerhalder

1 joint publications

Anthony W Tolcher

1 joint publications

Sarah Lindsey Davis

Frequent Collaborators

2 joint publications

Anneleen Daemen

2 joint publications

Edna Chow Maneval

2 joint publications

Pratik S Multani

2 joint publications

Melissa R Junttila

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

8.4K
High-Throughput <em>In Vitro</em> Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput <em>In Vitro</em> Assay using Patient-Derived Tumor Organoids

Published on : Jun 14, 2021

5.3K
See more related videos

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

8.4K
High-Throughput <em>In Vitro</em> Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput <em>In Vitro</em> Assay using Patient-Derived Tumor Organoids

Published on : Jun 14, 2021

5.3K
See more related videos